Glucox Biotech has signed an agreement with Prof. Anders Arner of Karolinska Institutet for further testing of Glucox smal molecule NOX4 inhibitors in diabetic models.

Prof. Arner, Department of Physiology and Pharmacology, Division of Genetic Physiology, Karolinska Institutet, Stockholm has agreed to investigate the influence of several of Glucox’ proprietary compounds on parameters relevant to metabolic diseases in diabetic models.

Ref: Samocha-Bonet, D., et al (2009) Trends in Endocrinology and Metabolism, 21 (2), 83-88